Go to Hepatitis B Foundation home page

Samuel So, MD, FACS: "Eliminating the Voodoo from Hepatitis B"

Samuel So, M.D., FACS, the featured Keynote Speaker at the 3rd Annual B Informed Patient Conference: A Gathering of Friends (July 2002), presents "Eliminating the Voodoo from Hepatitis B". This presentation provides useful, easy-to-understand answers to common questions surrounding hepatitis B management and treatment.

The annual B Informed Patient Conference, sponsored by the Hepatitis B Foundation and the Hepatitis B Information and Support List, draws attendees from around the world and is the only conference geared specifically toward hepatitis B patients and families.

Dr. So is the Director of the Asian Liver Center and Liver Cancer Program at Stanford University, Stanford California, and is also the leader of the well-known Jade Ribbon Campaign, a national hepatitis B awareness effort. Additionally, Dr. So is a professor in the Department of Surgery at the Stanford University School of Medicine.

To start at the beginning of the presentation, simply click on one of the answer links (video, audio, or text-only) to the right of the first question, and follow the arrows in each successive page, to move to the next question. Alternatively, you can click on the answer to a specific question, and/or use the Questions link at the top of a Q&A page, to return to this list.

Questions Answer Formats
1. I have been affected by Hepatitis B. How can I become an advocate and help others with this disease?
2. Why is the hepatitis B virus called the silent killer?
3. Why isn’t hepatitis B recognized as a problem by the US government in the way that hepatitis C is?
4. Why is Hepatitis B such a problem with Asians?
5. Can the vaccine protect someone who has close contact with a chronically infected person?
6. Should adolescents and adults be vaccinated against hepatitis B?
7. Do you recommend universal vaccination and screening of high-risk groups?
8. Why is the term 'carrier' misleading?
9. Why is it inaccurate to refer to a person with chronic hepatitis B (HBV) as a 'healthy carrier'?
10. What are the available treatments for hepatitis B and what are they used for?
11. Who needs a liver biopsy and who doesn't?
12. What are the guidelines for evaluating treatment among chronic carriers with elevated ALTs (liver enzyme levels)?
13. Should the e-antigen be used to determine the success/end point of treatment?
14. How do you determine which treatment should be used, and for how long?
15. Do you recommend treating patients with a high-viral load and normal ALTs (liver enzyme levels)?
16. How often should someone with chronic hepatitis B be screened for cancer?
17. What tests are used to screen for HCC (hepatocellular carcinoma)?
18. Can someone with normal ALTs (liver enzyme levels) develop liver cancer?
19. What tests are recommended for people with chronic hepatitis B?
20. Why is ultrasound used?
21. How do the ALT (liver enzyme levels) and AFP (alpha-fetoprotein) tests differ?
22. What liver cancer screening should be done in people with normal ALTs (liver enzyme levels)?
23. What is the prophylaxis treatment to prevent hepatitis B (HBV) recurrence after transplant?